Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
ARIA [NASD]
Ariad Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own1.90% Shs Outstand187.53M Perf Week7.04%
Market Cap1.74B Forward P/E- EPS next Y-0.77 Insider Trans-4.44% Shs Float181.79M Perf Month6.67%
Income-162.60M PEG- EPS next Q-0.26 Inst Own71.20% Short Float25.04% Perf Quarter44.62%
Sales105.40M P/S16.49 EPS this Y41.60% Inst Trans-0.03% Short Ratio7.59 Perf Half Y70.40%
Book/sh0.43 P/B21.56 EPS next Y26.70% ROA-33.80% Target Price8.14 Perf Year25.44%
Cash/sh1.88 P/C4.93 EPS next 5Y41.40% ROE-151.30% 52W Range4.90 - 9.23 Perf YTD34.93%
Dividend- P/FCF- EPS past 5Y-0.20% ROI-37.10% 52W High0.43% Beta1.37
Dividend %- Quick Ratio4.30 Sales past 5Y66.20% Gross Margin95.10% 52W Low89.18% ATR0.34
Employees379 Current Ratio4.30 Sales Q/Q695.20% Oper. Margin- RSI (14)68.92 Volatility3.97% 4.13%
OptionableYes Debt/Eq4.37 EPS Q/Q92.50% Profit Margin- Rel Volume1.32 Prev Close9.04
ShortableYes LT Debt/Eq4.28 EarningsMay 07 BMO Payout- Avg Volume6.00M Price9.27
Recom2.40 SMA209.27% SMA5014.13% SMA20040.09% Volume7,901,394 Change2.54%
Mar-25-14Resumed HC Wainwright Buy $14
Feb-26-14Upgrade Maxim Group Hold → Buy $11
Feb-26-14Downgrade Chardan Capital Markets Buy → Neutral
Jan-24-14Upgrade BMO Capital Markets Market Perform → Outperform $8 → $14
Jan-06-14Reiterated UBS Neutral $2.50 → $7.50
Dec-23-13Upgrade Chardan Capital Markets Neutral → Buy $9
Dec-20-13Reiterated BMO Capital Markets Market Perform $4 → $8
Dec-10-13Upgrade Stifel Hold → Buy $7
Oct-21-13Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $4
Oct-14-13Downgrade Argus Hold → Sell
Oct-10-13Reiterated Oppenheimer Outperform $24 → $7
Oct-10-13Downgrade Summer Street Research Buy → Neutral
Oct-10-13Downgrade Chardan Capital Markets Buy → Neutral
Oct-10-13Downgrade Barclays Overweight → Underweight $25 → $4
Oct-09-13Downgrade Maxim Group Buy → Hold $24
Sep-30-13Upgrade Oppenheimer Perform → Outperform $23 → $24
Sep-30-13Reiterated Maxim Group Buy $26 → $24
Sep-04-13Initiated Chardan Capital Markets Buy $28
Feb-26-13Reiterated Barclays Overweight $30 → $29
Jan-03-13Reiterated UBS Buy $29 → $26
Apr-21-15 07:35AM  ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting at noodls
07:35AM  ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting Business Wire
Apr-17-15 07:45AM  ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer at noodls
07:35AM  ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer Business Wire
05:59AM  Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech at TheStreet
Apr-15-15 02:41PM  Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capitals Top Picks Beat the Market at Insider Monkey
Apr-14-15 01:30PM  Five companies that may be looking to buy Ariad Pharmaceuticals at bizjournals.com
Apr-06-15 07:51AM  ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada at noodls
07:35AM  ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada Business Wire
Apr-03-15 05:24PM  3 Risks Ariad Investors Ought to Know About at Investopedia
Mar-27-15 06:07PM  3 Things Ariad Has to Do to Be Profitable in 2018 at Investopedia
06:50AM  The young & the restless: 6 who are hot at CNBC
Mar-25-15 04:09PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:37AM  ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court at noodls
09:28AM  ARIAD Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court Business Wire
Mar-24-15 07:39AM  ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel at noodls
07:35AM  ARIAD and Medison Pharma Announce Approval of Iclusig (Ponatinib) in Israel Business Wire
Mar-19-15 08:06AM  ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting at noodls
07:35AM  ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting Business Wire
Mar-18-15 01:31PM  MIT says cancer drug costs have outpaced quality increases at bizjournals.com
Mar-13-15 04:07PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-11-15 02:25PM  Activist investor at Ariad Pharmaceuticals has long history of wins at bizjournals.com
Mar-10-15 04:40PM  ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court at noodls
04:20PM  ARIAD Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court Business Wire
Feb-24-15 06:14PM  Why Ariad Pharmaceuticals Shares Are Undervalued at Barrons.com
12:05PM  ARIAD to Present at the Cowen and Company 35th Annual Health Care Conference at noodls
07:35AM  ARIAD to Present at the Cowen and Company 35th Annual Health Care Conference Business Wire
Feb-21-15 03:04PM  Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capitals Top Stock Picks and New Moves at Insider Monkey
Feb-20-15 05:34PM  Arista and Noodles are big market movers +10.87%
02:36PM  Ariad's 2nd largest shareholder says it wants Berger replaced as CEO at bizjournals.com
02:06PM  Technical Breakout In Ariad Pharmaceuticals Benzinga
01:37PM  Most active Nasdaq-traded stocks AP
11:32AM  Call buyers coming back to Ariad optionMONSTER
11:24AM  Activists want 'imminent retirement' of Ariad CEO at CNBC
10:05AM  Sarissa Capital mounts proxy fight to oust Ariad CEO Reuters
09:23AM  ARIAD Confirms Receipt of Sarissa Capital Managements Nomination of Director Candidates Business Wire
07:09AM  Activist Hedge Fund Seeks Firing of Ariad Pharma CEO Berger at TheStreet
06:52AM  Sarissa Capital seeks Ariad Pharma's CEO's ouster Reuters
Feb-19-15 03:16PM  Ariad's financials fail to impress as reports of CEO ouster continue at American City Business Journals
09:05AM  ARIAD (ARIA) Posts Narrower-than-Expected Q4 Loss - Tale of the Tape Zacks
08:43AM  Ariad reports 4Q loss AP
08:30AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:41AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
07:35AM  ARIAD Reports 2014 Financial Results, Provides 2015 Financial Guidance and Outlines Strategic Objectives Business Wire
07:07AM  Q4 2014 ARIAD Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
Feb-18-15 10:40AM  Will ARIAD (ARIA) Impress on Iclusig Sales this Earnings? - Analyst Blog Zacks
08:33AM  Why Ariad Pharmaceuticals (ARIA) Might Surprise This Earnings Season - Tale of the Tape Zacks
Feb-17-15 04:00PM  Can Actavis (ACT) Keep the Earnings Streak Alive in Q4? - Analyst Blog Zacks
08:51AM  Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 6.6% - Tale of the Tape Zacks
Feb-16-15 03:30PM  Will Agios (AGIO) Surprise Estimates This Earnings Season? - Analyst Blog Zacks
01:00PM  Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog Zacks
Feb-13-15 05:18PM  Stock Pops & Drops: SDRL, LVS, ARIA & JCP CNBC +6.52%
10:06AM  Can Radius Health (RDUS) Surprise This Earnings Season? - Analyst Blog Zacks
08:35AM  Activist fund Sarissa said to seek Ariad CEO change at CNBC
07:54AM  Early movers: GPS, ANF, VFC, DTE, CAG & more at CNBC
Feb-12-15 06:58PM  Sarissa Capital seeks to replace Ariad CEO - CNBC Reuters
Feb-11-15 07:35AM  ARIAD to Present at the RBC Capital Markets Healthcare Conference Business Wire
Feb-10-15 02:40PM  Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog Zacks
Feb-06-15 09:54AM  Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog Zacks
Feb-03-15 07:35AM  ARIAD to Present at the Leerink Global Healthcare Conference Business Wire
Feb-02-15 04:40PM  Will Pacific Biosciences (PACB) Surprise on Earnings in Q4? - Analyst Blog Zacks
02:40PM  Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog Zacks
Jan-30-15 12:38PM  3 Biotechs Looking Good this Earnings Season - Earnings ESP Zacks
Jan-29-15 07:35AM  ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2014 Financial Results Business Wire
Jan-22-15 07:35AM  ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer Business Wire
Jan-21-15 02:00PM  ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog Zacks
Jan-20-15 07:35AM  ARIAD Announces Final Decision from European Commission Endorsing Iclusigs Approved Indications Throughout Europe Business Wire
Jan-14-15 06:05PM  ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline - Analyst Blog Zacks
02:00PM  Transforming medicine CNBC
06:01AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
Jan-13-15 01:47PM  Ariad CEO: Expanding Iclusig CNBC -8.61%
11:20AM  Ariad lays out plan to get in the black by 2018 with $400M in revenue at American City Business Journals
07:35AM  ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years Business Wire
Jan-09-15 11:57AM  How to play the JPMorgan health conference at CNBC
Jan-07-15 04:16PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online +5.07%
Jan-06-15 07:35AM  ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015 Business Wire -6.06%
Dec-30-14 04:18PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
07:35AM  ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries Business Wire
Dec-23-14 01:30PM  Ariad nabs $77.5 million in licensing pact at bizjournals.com -5.67%
07:00AM  ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries Business Wire
Dec-22-14 07:35AM  ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-14 09:02AM  Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) at TheStreet +9.23%
Dec-11-14 04:16PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -7.69%
10:57AM  Mid-Morning Market Update: Markets Surge; Lululemon Profit Beats Expectations Benzinga
09:14AM  Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? at TheStreet
08:56AM  Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers TheStreet
08:06AM  UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak Benzinga
Dec-09-14 07:35AM  ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial Business Wire
07:35AM  ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia Business Wire
Dec-08-14 07:35AM  ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Business Wire
Nov-25-14 07:52AM  Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Zacks
Nov-24-14 10:04AM  ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today at TheStreet +9.66%
07:35AM  ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Business Wire
Nov-14-14 01:04PM  ARIAD PHARMACEUTICALS INC Financials EDGAR Online Financials
Nov-12-14 03:59PM  Stalking an Entry Into Ariad Pharmaceutical Yahoo Finance Blogs
Nov-09-14 07:09PM  10-Q for ARIAD Pharmaceuticals, Inc. Company Spotlight
Nov-07-14 04:52PM  ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-06-14 09:44AM  ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting Business Wire +5.80%
Nov-05-14 08:30AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:57AM  Ariad tops 3Q profit forecasts AP
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERGER HARVEY J M DChairman & CEOMar 26Option Exercise7.56150,0001,134,0001,446,175Mar 30 04:21 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 23Option Exercise0.0013,3330446,981Mar 23 05:45 PM
Duvall Martin JEVP, CCOMar 23Sale8.578347,14554,950Mar 23 05:59 PM
Haluska FrankSVP, Clinical R&D, CMOMar 23Sale8.553,30028,229114,124Mar 23 05:54 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 23Sale8.554,03334,491104,881Mar 23 06:16 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 23Sale8.556,66757,016440,314Mar 23 05:45 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 23Sale8.554,16735,630305,209Mar 23 06:02 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 23Sale8.553,00025,661117,797Mar 23 06:06 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 23Sale8.562,00017,118159,907Mar 23 05:27 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 20Option Exercise0.004,0000228,449Mar 23 05:27 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 20Option Exercise0.006,0000120,797Mar 23 06:06 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 20Option Exercise0.008,3330309,376Mar 23 06:02 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 20Option Exercise0.007,3330108,916Mar 23 06:16 PM
BERGER HARVEY J M DChairman & CEOMar 20Option Exercise0.0034,00001,320,654Mar 23 06:03 PM
Haluska FrankSVP, Clinical R&D, CMOMar 20Option Exercise0.006,0000117,424Mar 23 05:54 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 20Sale8.845,41747,910433,648Mar 23 05:45 PM
Haluska FrankSVP, Clinical R&D, CMOMar 20Sale8.853,57531,634111,424Mar 23 05:54 PM
Duvall Martin JEVP, CCOMar 20Sale8.854,00035,38154,117Mar 23 05:59 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 20Sale8.853,57531,627101,583Mar 23 06:16 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 20Sale8.845,41747,908301,043Mar 23 06:02 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 20Sale8.854,00035,390114,797Mar 23 06:06 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 20Sale8.852,37521,026157,907Mar 23 05:27 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Option Exercise4.9631,490156,167460,971Mar 23 05:45 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 19Option Exercise0.004,7500226,824Mar 23 05:27 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 19Option Exercise0.008,0000118,797Mar 23 06:06 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 19Option Exercise0.0010,8330306,460Mar 23 06:02 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 19Option Exercise1.6914,37524,255114,504Mar 23 06:16 PM
BERGER HARVEY J M DChairman & CEOMar 19Option Exercise0.0036,00001,286,654Mar 23 06:03 PM
Duvall Martin JEVP, CCOMar 19Option Exercise0.008,000058,117Mar 23 05:59 PM
Haluska FrankSVP, Clinical R&D, CMOMar 19Option Exercise0.006,5000114,999Mar 23 05:54 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Sale9.0020,657185,913440,314Mar 23 05:45 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 19Sale9.009,34684,114105,158Mar 23 06:16 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 16Option Exercise1.307,5009,750145,222Mar 18 04:23 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 16Sale8.6234,425296,651110,797Mar 18 04:23 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 20Option Exercise3.5449,035173,419453,231Feb 24 04:23 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 20Sale8.0049,035392,280428,232Feb 24 04:23 PM
BERGER HARVEY J M DChairman & CEOFeb 12Buy6.9012,50086,2801,864,286Feb 13 04:21 PM
BERGER HARVEY J M DChairman & CEOFeb 11Buy6.7712,50084,5691,851,786Feb 13 04:21 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 02Option Exercise0.0029,3340124,633Feb 04 04:52 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 02Option Exercise0.0029,3340236,741Feb 04 04:14 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 02Option Exercise0.0029,3340310,294Feb 04 04:16 PM
Duvall Martin JEVP, CCOFeb 02Option Exercise0.0029,334064,784Feb 04 04:16 PM
BERGER HARVEY J M DChairman & CEOFeb 02Option Exercise0.0087,00001,250,564Feb 04 04:15 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 02Option Exercise0.0029,3340152,389Feb 04 04:18 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 02Option Exercise0.0029,3340442,899Feb 04 04:17 PM
Cantor Maria ESVP, Corporate Affairs and HRFeb 02Option Exercise0.0029,3340116,263Feb 04 04:19 PM
Cantor Maria ESVP, Corporate Affairs and HRFeb 02Sale6.3316,134102,089100,129Feb 04 04:19 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 02Sale6.3314,66792,820428,232Feb 04 04:17 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 02Sale6.3314,66792,823137,722Feb 04 04:18 PM
Duvall Martin JEVP, CCOFeb 02Sale6.3314,66792,82350,117Feb 04 04:16 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 02Sale6.3314,66792,849295,627Feb 04 04:16 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 02Sale6.3314,66792,826222,074Feb 04 04:14 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 02Sale6.3316,134102,107108,499Feb 04 04:52 PM
BERGER HARVEY J M DChairman & CEOJan 23Buy6.1812,50077,2501,839,286Jan 26 04:09 PM
BERGER HARVEY J M DChairman & CEOJan 22Buy6.1612,50076,9901,826,786Jan 26 04:09 PM
Schlesinger Sarah J.DirectorJan 14Buy6.251,3008,12515,600Jan 15 04:30 PM
Schlesinger Sarah J.DirectorJan 13Buy6.971,3009,06114,300Jan 15 04:30 PM
BERGER HARVEY J M DChairman & CEODec 18Buy6.5412,50081,7701,814,286Dec 19 04:29 PM
BERGER HARVEY J M DChairman & CEODec 17Buy6.1512,50076,8751,801,786Dec 19 04:29 PM
Schlesinger Sarah J.DirectorDec 17Buy6.111,3007,94313,000Dec 18 04:09 PM
Schlesinger Sarah J.DirectorDec 16Buy6.071,3007,89111,700Dec 18 04:09 PM
Cantor Maria ESVP, Corporate Affairs and HRNov 24Sale7.001,74912,24386,929Nov 25 04:22 PM
BERGER HARVEY J M DChairman & CEONov 20Buy6.1512,50076,8891,789,286Nov 21 04:18 PM
BERGER HARVEY J M DChairman & CEONov 19Buy6.1512,50076,8531,776,786Nov 21 04:18 PM
Schlesinger Sarah J.DirectorNov 12Buy6.221,3008,08610,400Nov 13 04:27 PM
Schlesinger Sarah J.DirectorNov 11Buy6.301,3008,1909,100Nov 13 04:27 PM
BERGER HARVEY J M DChairman & CEOOct 16Buy5.3912,50067,3181,764,286Oct 17 04:24 PM
BERGER HARVEY J M DChairman & CEOOct 15Buy5.1012,50063,7281,751,786Oct 17 04:24 PM
Schlesinger Sarah J.DirectorOct 15Buy5.031,3006,5397,800Oct 16 04:27 PM
Schlesinger Sarah J.DirectorOct 14Buy5.071,3006,5916,500Oct 16 04:27 PM
Schlesinger Sarah J.DirectorSep 10Buy5.751,3007,4755,200Sep 11 04:38 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerSep 09Option Exercise5.237,82540,925147,983Sep 11 04:41 PM
BERGER HARVEY J M DChairman & CEOSep 09Option Exercise5.23150,000784,5001,294,277Sep 11 04:39 PM
Schlesinger Sarah J.DirectorSep 09Buy5.931,3007,7093,900Sep 11 04:38 PM
BERGER HARVEY J M DChairman & CEOSep 03Buy6.3112,50078,8591,739,286Sep 11 04:39 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 02Option Exercise1.3026,25034,125179,705Sep 04 04:21 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 02Option Exercise5.2350,000261,500305,960Sep 04 04:24 PM
BERGER HARVEY J M DChairman & CEOSep 02Buy6.2212,50077,7781,726,786Sep 11 04:39 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 02Sale6.2250,000310,835280,960Sep 04 04:24 PM
Cantor Maria ESVP, Corporate Affairs and HRSep 02Sale6.212,69616,75388,678Sep 04 04:22 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 02Sale6.2256,650352,227123,055Sep 04 04:21 PM
DENNER ALEXANDER JDirectorAug 15Buy5.83850,0004,955,5007,798,665Aug 19 06:04 PM
Schlesinger Sarah J.DirectorAug 13Buy5.711,3007,4232,600Sep 11 04:38 PM
Schlesinger Sarah J.DirectorAug 12Buy5.521,3007,1761,300Sep 11 04:38 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerJul 15Option Exercise0.008,0000238,642Jul 17 05:04 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 15Option Exercise0.0014,0000418,129Jul 17 05:02 PM
Haluska FrankSVP, Clinical R&D, CMOJul 15Option Exercise0.008,000097,907Jul 17 05:01 PM
FITZGERALD EDWARD MExecutive VP, CFOJul 15Option Exercise0.0014,0000285,524Jul 17 05:00 PM
Duvall Martin JEVP, CCOJul 15Option Exercise0.002,800036,363Jul 17 04:58 PM
BERGER HARVEY J M DChairman & CEOJul 15Option Exercise0.0036,80001,138,177Jul 17 04:59 PM
Cantor Maria ESVP, Corporate Affairs and HRJun 02Sale6.903,71325,61184,461Jun 04 04:29 PM